New drug trial targets debilitating eye muscle weakness
NCT ID NCT07463521
Summary
This study aims to test whether an investigational drug called rozanolixizumab can safely reduce eye muscle weakness and improve quality of life for adults with ocular myasthenia gravis. About 120 participants will receive either the drug or a placebo for 43 days while researchers measure changes in their symptoms and daily function. The goal is to control the disease's effects, not to cure it, as ongoing management would still be needed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.